PECAM1 and endothelial dysfunction: This study suggested that ox-LDL stimulation reduced CD31, eNOS and NO levels as well as enhanced α-SMA and iNOS expression, which was reversed by LPAR5 silencing, implicating the improving effects of LPAR5 downregulation on ox-LDL-induced endothelial dysfunction.